CHOL

K981476 · Abbott Laboratories · CHH · Jun 25, 1998 · Clinical Chemistry

Device Facts

Record IDK981476
Device NameCHOL
ApplicantAbbott Laboratories
Product CodeCHH · Clinical Chemistry
Decision DateJun 25, 1998
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 862.1175
Device ClassClass 1

Intended Use

The Cholesterol assay is used for the quantitation of cholesterol in human serum or plasma. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.

Device Story

In vitro diagnostic assay for quantitative cholesterol determination in human serum or plasma; utilizes enzymatic hydrolysis via cholesterol esterase and oxidation via cholesterol oxidase to produce hydrogen peroxide; reaction with hydroxybenzoic acid and 4-aminoantipyrine forms a measurable quinoneimine dye chromophore. Used in clinical laboratory settings; operated by laboratory technicians. Output is a quantitative cholesterol concentration value used by physicians to diagnose and manage lipid metabolism disorders and hypercholesterolemia.

Clinical Evidence

Bench testing only. Method comparison against Roche Cobas Mira Plus yielded r=0.9887, slope=0.916, intercept=0.206 mg/dL. Validated against Abell-Kendall reference method in a CRMLN-certified lab. Precision studies: total %CV of 2.2% (Level 1) and 2.7% (Level 2). Linearity up to 530 mg/dL; limit of quantitation 0.970 mg/dL.

Technological Characteristics

In vitro clinical chemistry assay; enzymatic colorimetric method. Reagents include cholesterol esterase, cholesterol oxidase, hydroxybenzoic acid, and 4-aminoantipyrine. Analyzed on ALCYON Analyzer. Quantitative measurement of chromophore (quinoneimine dye).

Indications for Use

Indicated for the quantitative determination of cholesterol in human serum or plasma for the diagnosis and treatment of disorders involving excess blood cholesterol and lipid/lipoprotein metabolism disorders.

Regulatory Classification

Identification

A cholesterol (total) test system is a device intended to measure cholesterol in plasma and serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ # 月981476 Section II 510(k) Summary Cholesterol 510(k) April 23, 1998 Chol510k.lwp Section II {1}------------------------------------------------ ## 510(k) Summary #### Submitter's Name/Address Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038 Contact Person Mark Littlefield Section Manager MS 1-8 Regulatory Affairs (972) 518-7861 Fax (972) 753-3367 | Date of Preparation of this Summary: | April 23, 1998 | |--------------------------------------------------|----------------| | Device Trade or Proprietary Name: | Chol | | Device Common/Usual Name or Classification Name: | Cholesterol | | Classification Number/Class: | 75CHH/Class I | This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: #### Test Description: Cholesterol is an in vitro diagnostic assay for the quantitative determination of cholesterol in human serum or plasma. The Cholesterol assay is a clinical chemistry assay in which cholesterol esters are enzymatically hydrolysed by cholesterol esterase to cholesterol and free fatty acids. Free cholesterol, including that originally present, is then oxidized by cholesterol oxidase to cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide combines with Hydroxybenzoic Acid and 4-aminoantipyrine to form a chromophore (quinoneimine dye) which can be measured. Cholesterol 510(k) April 23, 1998 Chol510k.lwp Section II Page 1 {2}------------------------------------------------ #### Substantial Equivalence: The Cholesterol assay is substantially equivalent to the following device: - Roche® Cobas Mira® Plus Automated Chemistry System Cholesterol assay . (K896239) These assays yield similar Performance Characteristics. Similarities to Roche: - Both assays are in vitro clinical chemistry methods. 새 - Both assays can be used for the quantitative determination of cholesterol. . - Both assays vield similar clinical results. . - Both assays have the same assay range. . Differences to Roche: - There is a minor difference in the analysis medium. . #### Intended Use: The Cholesterol assay is used for the quantitation of cholesterol in human serum or plasma. #### Performance Characteristics: Comparative performance studies were conducted using the ALCYON™ Analyzer. The Cholesterol assay method comparison vielded acceptable correlation with the Roche Cobas Mira Plus Automated Chemistry System Cholesterol assay. The correlation coefficient = 0.9887, slope = 0.916, and Y-intercept = 0.206 mg/dL. The ALCYON Cholesterol reagent was validated against the Abell-Kendall reference method in a CDC-Certified Cholesterol Reference Method Network Laboratory (CRMLN). A copy of the CRMLN Certificate of Traceability is included in Section III.F. Precision studies were conducted using the Cholesterol assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 111 control is is 2.2% and Level 2/Panel 1 12 is 2.7%. The Cholesterol assay is linear up to 530 mg/dL. Section II Page 2 {3}------------------------------------------------ The limit of quantitation (sensitivity) of the Cholesterol assay is 0.970 mg/dL. These data demonstrate that the performance of the Cholesterol assay is substantially equivalent to the performance of the Roche Cobas Mira Plus Automated Chemistry System Cholesterol assay. #### Conclusion: The Cholesterol assay is substantially equivalent to the Roche Cobas Mira Plus Automated Chemistry System Cholesterol assay as demonstrated by results obtained in the studies. Cholesterol 510(k) April 23, 1998 Chol510k.lwp Section II Page 3 Image /page/3/Picture/5 description: The image shows a sequence of numbers. The numbers are 0000014. The numbers are printed in a bold, slightly distressed font, giving them a vintage or aged appearance. The background is plain and white. {4}------------------------------------------------ Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The eagle faces to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 JUN 2 5 1998 Mark Littlefield Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038 K981476 Re : Cholesterol Regulatory Class : I Product Code: CHH Dated: April 23, 1998 Received: April 24, 1998 Dear Mr. Littlefield: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ਸੁਤੰ substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical General regulation (21 CFR Part 820) and that, Devices: through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations. {5}------------------------------------------------ Page 2 Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your marrosed promits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, Steven Bitman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________ Cholesterol __________________________________________________________________________________________________________________________________________________________________ Device Name: _________________________________________________________________________________________________________________________________________________________________ Indications For Use: Cholesterol The Cholesterol assay is used for the quantitation of cholesterol in human serum or plasma. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders. Carroll C. Bensinger Alfred Montgomery (Division Sign-Off) Division of Clinical Laboratory Dev 510(k) Number (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Concyrence of CDRH, Office of Device Evaluation (ODE) Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________ Prescription Use V OR (Per 21 CFR 801.109) (Optional Format 1-2-96)
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%